Molecular Diagnostics Market Analysis and Segment Forecasts, 2016 to 2024

1
Your Catalyst to a Lucrative Business
Molecular Diagnostics Market Share, Size,
Analysis, Growth, Trends and Forecasts to 2024
Hexa Research
Molecular Diagnostics Market To Grow At 9 CAGR
Till 2024
The Molecular Diagnostics Market was valued at
over USD 6.40 billion in 2015. It is likely to
grow at a CAGR of around 9 during the forecast
period (2016-2024).
Increasing prevalence of infectious diseases,
cancer, genetic disorders, and other contagious
disease are likely to drive the molecular
diagnostics industry. Hospital acquired
infections and other communicable infections are
expected to boost market growth in the coming
eight years. Moreover, prenatal genetic testing
is also expected to increase the adoption of this
diagnostics.
Unhealthy lifestyle can further contribute to
large number of people getting afflicted with
chronic ailments like cardiovascular disorders
and diabetes. This with further propel market
growth in the coming years. Molecular diagnostics
market is divided into products, technologies,
applications, test location, and regions.
Browse Details of Report _at_ https//www.hexaresearc
h.com/research-report/molecular-diagnostics- indus
try
Follow Us
2
Your Catalyst to a Lucrative Business
On the basis of products, the market is split
into instruments, reagents, and others. Reagents
segment held the largest share in 2015 with
revenues exceeding USD 3.5 billion. It is
expected to grow at a CAGR surpassing 12.
Instruments segment is expected to show a
significant growth in the coming years.
Technologies consist of polymerase chain reaction
(PCR), in-situ hybridization, chips and
microarrays, mass spectrometery, DNA sequencing,
transportation mediated amplification, and
others. PCR held the largest market share of over
USD 2.5 billion in 2015. Growth of this segment
can be attributed to its high incorporation among
the researchers and healthcare professionals. DNA
sequencing is likely to show a growth of about
16 CAGR in the coming years.
Applications encompass oncology,
pharmacogenomics, infectious diseases, genetic
testing, neurological diseases, cardiovascular
diseases, and others. Infectious diseases segment
was the largest application holding market share
exceeding 45 in 2015.
Oncology segment is anticipated to show a CAGR of
about 13 till 2024. Rising awareness among
people regarding early cancer diagnosis is the
key aspect propelling market growth of the
segment.
Test location comprises of point of care (PoC),
self test or over the counter (OTC), and central
laboratories. Central laboratories dominated the
market with over 60 shares in 2015. The growth
of the central laboratories can be attributed to
their large prominence in underdeveloped
countries, rising awareness about early detection
of diseases, and high procedure volumes.
The PoC is expected to project a lucrative growth
with a CAGR of more than 14. The growth of this
segment can be attributed to the increasing
demand of bedside patient monitoring and
innovative technological devices.
Regions are fragmented into North America, Latin
America, Europe, Asia Pacific, and the Middle
East Africa (MEA). America dominated the market
with over 40 revenue share. Asia Pacific is
likely to exhibit a growth of around 12CAGR in
the coming years.
The key global players of the molecular
diagnostics market include Siemens Healthcare
GmbH, Novartis AG (Grifols), F. Hoffmann-La Roche
Limited, and Johnson Johnson.
Browse Related Category Market Reports _at_
https//www.hexaresearch.com/research- category/bi
otechnology-industry
Follow Us
3
Your Catalyst to a Lucrative Business
Table of Contents of Molecular Diagnostics Market
Chapter 1 Methodology Scope 1.1 Research
Methodology
1.1.1 Initial data exploration
1.1.2 Statistical modeling and forecast 1.1.3
Industry insights and validation 1.2 List of Data
Sources
Chapter 2 Executive Summary 2.1 Molecular
diagnostics industry 3600 perspective, 2016 - 2024
Chapter 3 Molecular Diagnostics Industry
Insights 3.1 Market segmentation 3.2 Industry
size, forecast and growth expectations, 2016 -
2024 3.3 Industry dynamics
3.3.1 Growth drivers
3.3.1.1 Technological advancements 3.3.1.2
Growing POC demand 3.3.1.3 Increasing geriatric
population 3.3.1.4 Considerable RD
initiatives 3.3.1.5 Upward trend in disease
prevalence 3.3.2 Industry pitfalls and
challenges 3.3.2.1 Unclear regulatory
landscape 3.3.2.2 Cost concerns
3.4 Key growth opportunities
3.4.1 Regional opportunities 3.4.2 Disease type
opportunities 3.5 Porters analysis 3.6 PESTEL
analysis 3.7 Company market share analysis,
2016 3.7.1 Key product landscape
3.7.2 Competitive landscape
Chapter 4 Molecular Diagnostics Infectious
Disease Insights 4.1 Molecular diagnostics market
share by infectious disease, 2016 2024 4.2
Flu 4.2.1 Market estimates and forecast, 2016 -
2024 (USD Million) 4.2.2 Market estimates and
forecast by region, 2016 - 2024 (USD Million) 4.3
RSV (Respiratory Syncytial Virus) 4.3.1 Market
estimates and forecast, 2016 - 2024 (USD
Million) 4.3.2 Market estimates and forecast by
region, 2016 - 2024 (USD Million) 4.4
Tuberculosis 4.4.1 Market estimates and forecast,
2016 - 2024 (USD Million) 4.4.2 Market estimates
and forecast by region, 2016 - 2024 (USD
Million) 4.5 Meningitis
Follow Us
4
Your Catalyst to a Lucrative Business
4.5.1 Market estimates and forecast, 2016 - 2024
(USD Million) 4.5.2 Market estimates and forecast
by region, 2016 - 2024 (USD Million) 4.6
Chlamydia 4.6.1 Market estimates and forecast,
2016 - 2024 (USD Million) 4.6.2 Market estimates
and forecast by region, 2016 - 2024 (USD
Million) 4.7 Gonorrhea 4.7.1 Market estimates and
forecast, 2016 - 2024 (USD Million) 4.7.2 Market
estimates and forecast by region, 2016 - 2024
(USD Million) 4.8 HIV
4.8.1 Market estimates and forecast, 2016 - 2024
(USD Million) 4.8.2 Market estimates and forecast
by region, 2016 - 2024 (USD Million) 4.9
Hepatitis C 4.9.1 Market estimates and forecast,
2016 - 2024 (USD Million) 4.9.2 Market estimates
and forecast by region, 2016 - 2024 (USD
Million) 4.10 Hepatitis B 4.10.1 Market estimates
and forecast, 2016 - 2024 (USD Million) 4.10.2
Market estimates and forecast by region, 2016 -
2024 (USD Million) 4.11 HPV 4.11.1 Market
estimates and forecast, 2016 - 2024 (USD
Million) 4.11.2 Market estimates and forecast by
region, 2016 - 2024 (USD Million) 4.12 STD 4.12.1
Market estimates and forecast, 2016 - 2024 (USD
Million) 4.12.2 Market estimates and forecast by
region, 2016 - 2024 (USD Million) 4.13
Dengue 4.13.1 Market estimates and forecast, 2016
- 2024 (USD Million) 4.13.2 Market estimates and
forecast by region, 2016 - 2024 (USD
Million) 4.14 H. pylori 4.14.1 Market estimates
and forecast, 2016 - 2024 (USD Million) 4.14.2
Market estimates and forecast by region, 2016 -
2024 (USD Million) 4.15 TORCH 4.15.1 Market
estimates and forecast, 2016 - 2024 (USD
Million) 4.15.2 Market estimates and forecast by
region, 2016 - 2024 (USD Million) 4.16 Others
4.16.1 Market estimates and forecast, 2016 - 2024
(USD Million) 4.16.2 Market estimates and
forecast by region, 2016 - 2024 (USD Million)
Chapter 5 Molecular Diagnostics Technology
Insights 5.1 Molecular diagnostics market share
by technology, 2016 2024 5.2 PCR (Polymerase
Chain Reaction) technology
5.2.1 Market estimates and forecast, 2016 - 2024
(USD Million) 5.2.2 Market estimates and forecast
by region, 2016 - 2024 (USD Million) 5.2.3 Real
time PCR 5.2.3.1 Market estimates and forecast,
2016 - 2024 (USD Million) 5.2.3.2 Market
estimates and forecast by region, 2016 - 2024
(USD Million) 5.2.4 DNA/RNA Purification
5.2.4.1 Market estimates and forecast, 2016 -
2024 (USD Million)
Follow Us
5
Your Catalyst to a Lucrative Business
5.2.4.2 Market estimates and forecast by region,
2016 - 2024 (USD Million) 5.3 Others
5.3.1 Market estimates and forecast, 2016 - 2024
(USD Million) 5.3.2 Market estimates and forecast
by region, 2016 - 2024 (USD Million)
Chapter 6 Molecular Diagnostics Regional
Insights 6.1 Molecular diagnostics market share,
by region, 2016 2024 6.2 North America
6.2.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.2.2 Market estimates
by technology, 2016 - 2024 (USD Million) 6.2.3
U.S. 6.2.3.1 Market estimates by infectious
disease, 2016 - 2024 (USD Million) 6.2.3.1 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.2.4 Canada
6.2.4.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.2.4.1 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.3 Europe
6.3.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.3.2 Market estimates
by technology, 2016 - 2024 (USD Million) 6.3.3
Germany 6.3.3.1 Market estimates by infectious
disease, 2016 - 2024 (USD Million) 6.3.3.2 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.3.4 UK 6.3.4.1 Market estimates by
infectious disease, 2016 - 2024 (USD
Million) 6.3.4.2 Market estimates by technology,
2016 - 2024 (USD Million) 6.3.5 France 6.3.5.1
Market estimates by infectious disease, 2016 -
2024 (USD Million) 6.3.5.2 Market estimates by
technology, 2016 - 2024 (USD Million) 6.3.6
Spain 6.3.6.1 Market estimates by infectious
disease, 2016 - 2024 (USD Million) 6.3.6.2 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.3.7 Portugal 6.3.7.1 Market estimates
by infectious disease, 2016 - 2024 (USD
Million) 6.3.7.2 Market estimates by technology,
2016 - 2024 (USD Million) 6.3.8 Italy 6.3.8.1
Market estimates by infectious disease, 2016 -
2024 (USD Million) 6.3.8.2 Market estimates by
technology, 2016 - 2024 (USD Million) 6.3.9
Russia 6.3.9.1 Market estimates by infectious
disease, 2016 - 2024 (USD Million) 6.3.9.2 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.3.10 Denmark
6.3.10.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.3.10.2 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.3.11 Norway
6.3.11.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.3.11.2 Market
estimates by technology, 2016 - 2024 (USD Million)
Follow Us
6
Your Catalyst to a Lucrative Business
6.3.12 Sweden
6.3.12.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.3.12.2 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.3.13 Israel
6.3.13.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.3.13.2 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.4 Asia Pacific
6.4.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.4.2 Market estimates
by technology, 2016 - 2024 (USD Million) 6.4.3
Japan 6.4.3.1 Market estimates by infectious
disease, 2016 - 2024 (USD Million) 6.4.3.1 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.4.4 China 6.4.4.1 Market estimates by
infectious disease, 2016 - 2024 (USD
Million) 6.4.4.2 Market estimates by technology,
2016 - 2024 (USD Million) 6.4.5 India 6.4.5.1
Market estimates by infectious disease, 2016 -
2024 (USD Million) 6.4.5.2 Market estimates by
technology, 2016 - 2024 (USD Million) 6.4.6 Sri
Lanka 6.4.6.1 Market estimates by infectious
disease, 2016 - 2024 (USD Million) 6.4.6.2 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.4.7 Malaysia 6.4.7.1 Market estimates
by infectious disease, 2016 - 2024 (USD
Million) 6.4.7.2 Market estimates by technology,
2016 - 2024 (USD Million) 6.4.8 Pakistan 6.4.8.1
Market estimates by infectious disease, 2016 -
2024 (USD Million) 6.4.8.2 Market estimates by
technology, 2016 - 2024 (USD Million) 6.4.9
Philippines 6.4.9.1 Market estimates by
infectious disease, 2016 - 2024 (USD
Million) 6.4.9.2 Market estimates by technology,
2016 - 2024 (USD Million) 6.4.10 South
Korea 6.4.10.1 Market estimates by infectious
disease, 2016 - 2024 (USD Million) 6.4.10.2
Market estimates by technology, 2016 - 2024 (USD
Million) 6.4.11 Australia 6.4.11.1 Market
estimates by infectious disease, 2016 - 2024 (USD
Million) 6.4.11.2 Market estimates by technology,
2016 - 2024 (USD Million) 6.4.12 New
Zealand 6.4.12.1 Market estimates by infectious
disease, 2016 - 2024 (USD Million) 6.4.12.2
Market estimates by technology, 2016 - 2024 (USD
Million) 6.4.13 Vietnam 6.4.13.1 Market estimates
by infectious disease, 2016 - 2024 (USD
Million) 6.4.13.2 Market estimates by technology,
2016 - 2024 (USD Million) 6.4.14 Thailand
6.4.14.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.4.14.2 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.5 Latin America
Follow Us
7
Your Catalyst to a Lucrative Business
6.5.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.5.2 Market estimates
by technology, 2016 - 2024 (USD Million) 6.5.3
Mexico 6.5.3.1 Market estimates by infectious
disease, 2016 - 2024 (USD Million) 6.5.3.2 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.5.4 Brazil 6.5.4.1 Market estimates by
infectious disease, 2016 - 2024 (USD
Million) 6.5.4.2 Market estimates by technology,
2016 - 2024 (USD Million) 6.5.5 Argentina 6.5.5.1
Market estimates by infectious disease, 2016 -
2024 (USD Million) 6.5.5.2 Market estimates by
technology, 2016 - 2024 (USD Million) 6.5.6
Colombia 6.5.6.1 Market estimates by infectious
disease, 2016 - 2024 (USD Million) 6.5.6.2 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.5.7 Chile 6.5.7.1 Market estimates by
infectious disease, 2016 - 2024 (USD
Million) 6.5.7.2 Market estimates by technology,
2016 - 2024 (USD Million) 6.5.8 Peru
6.5.8.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.5.8.2 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.6 Africa
6.6.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.6.2 Market estimates
by technology, 2016 - 2024 (USD Million) 6.6.3
South Africa 6.6.3.1 Market estimates by
infectious disease, 2016 - 2024 (USD
Million) 6.6.3.2 Market estimates by technology,
2016 - 2024 (USD Million) 6.6.4 Nigeria 6.6.4.1
Market estimates by infectious disease, 2016 -
2024 (USD Million) 6.6.4.2 Market estimates by
technology, 2016 - 2024 (USD Million) 6.6.5
Morocco 6.6.5.1 Market estimates by infectious
disease, 2016 - 2024 (USD Million) 6.6.5.2 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.6.6 Egypt
6.6.6.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.6.6.2 Market
estimates by technology, 2016 - 2024 (USD
Million) 6.7 Middle East
6.7.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.7.2 Market estimates
by technology, 2016 - 2024 (USD Million) 6.7.3
Saudi Arabia 6.7.3.1 Market estimates by
infectious disease, 2016 - 2024 (USD
Million) 6.7.3.2 Market estimates by technology,
2016 - 2024 (USD Million) 6.7.4 UAE 6.7.4.1
Market estimates by infectious disease, 2016 -
2024 (USD Million) 6.7.4.2 Market estimates by
technology, 2016 - 2024 (USD Million) 6.7.5 Jordan
6.7.5.1 Market estimates by infectious disease,
2016 - 2024 (USD Million)
Follow Us
8
Your Catalyst to a Lucrative Business
6.7.5.2 Market estimates by technology, 2016 -
2024 (USD Million) 6.7.6 Qatar
6.7.6.1 Market estimates by infectious disease,
2016 - 2024 (USD Million) 6.7.6.2 Market
estimates by technology, 2016 - 2024 (USD Million)
Chapter 7 Competitive Insights 7.1 Abbott
Laboratories 7.2 Alere Inc. 7.3 Bayer
Healthcare 7.4 Becton Dickinson 7.5
bioMerieux 7.6 Bio-Rad Laboratories 7.7
Cepheid 7.8 Dako 7.9 Danaher Corporation 7.10
Hologic (Gen Probe) 7.11 Johnson Johnson 7.12
Novartis (Grifols) 7.13 Qiagen N.V. 7.14 Roche
Diagnostics 7.15 Siemens Healthcare 7.16 Sysmex
Corporation
Follow Us
9
Your Catalyst to a Lucrative Business
About Us
Hexa Research is a market research and consulting
organization, offering industry reports, custom
research and consulting services to a host of key
industries across the globe. We offer
comprehensive business intelligence in the form
of industry reports which help our clients obtain
clarity about their business environment and
enable them to undertake strategic growth
initiatives.
Contact Us
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018 United States
Phone [phone] Email sales_at_hexaresearch.c
om Website - https//www.hexaresearch.com
Follow Us